Nanovis received a National Institutes of Health (NIH) grant supporting pre-clinical studies of FortiCore® deeply-porous interbody fusion devices, enhanced with nanotube technology. The FortiCore device will be studied with Nanovis’ nanosurfaced FortiFix® pedicle screws to determine their potential impact on improving recovery following spinal fusion.
To date, Nanovis’ spinal and soft tissue regeneration nanotechnology platforms have received eight competitive, peer-reviewed grants from the NIH and other research organizations.
FortiCore sterile-packed interbody fusion devices received FDA 510(k) clearance in late 3Q14. Nanovis received its first NIH grant in support of FortiCore one year later.
Matt Hedrick, CEO of Nanovis was one of four executives who offered a take on innovation for BONEZONE readers, in 2013:
“At Nanovis, we’ve identified large orthopaedic and soft tissue implant markets with clinical needs that could be better met by our technology vs. the current option, and where the implants are otherwise relatively undifferentiated.”
Nanovis received a National Institutes of Health (NIH) grant supporting pre-clinical studies of FortiCore® deeply-porous interbody fusion devices, enhanced with nanotube technology. The FortiCore device will be studied with Nanovis' nanosurfaced FortiFix® pedicle screws to determine their potential impact on improving recovery following spinal...
Nanovis received a National Institutes of Health (NIH) grant supporting pre-clinical studies of FortiCore® deeply-porous interbody fusion devices, enhanced with nanotube technology. The FortiCore device will be studied with Nanovis’ nanosurfaced FortiFix® pedicle screws to determine their potential impact on improving recovery following spinal fusion.
To date, Nanovis’ spinal and soft tissue regeneration nanotechnology platforms have received eight competitive, peer-reviewed grants from the NIH and other research organizations.
FortiCore sterile-packed interbody fusion devices received FDA 510(k) clearance in late 3Q14. Nanovis received its first NIH grant in support of FortiCore one year later.
Matt Hedrick, CEO of Nanovis was one of four executives who offered a take on innovation for BONEZONE readers, in 2013:
“At Nanovis, we’ve identified large orthopaedic and soft tissue implant markets with clinical needs that could be better met by our technology vs. the current option, and where the implants are otherwise relatively undifferentiated.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
